Evidence map›Paper›PMID 28475559›Full record

ArticleAnnals of surgery2018

Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer.

Chi-Fu Jeffrey Yang, Derek Y Chan, Shivani A Shah, Babatunde A Yerokun, Xiaofei F Wang, Thomas A D'Amico, Mark F Berry, David H Harpole

Registry-linked trialAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Annals of surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04696939 (Clinical Study of Programmed Cell Death Ligand-1), which is not on this map. Cited by 73 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04696939 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Clinical Study of Programmed Cell Death Ligand-1(PD-L1) Antibody (Atezolizumab) Plus Chemotherapy (Carboplatin Plus Etoposide) for Previously Untreated Small Cell Lung Cancer

TypeinterventionalSponsorShanghai Pulmonary Hospital, Shanghai, ChinaRan2021 to 2023Enrolled100ConditionsSmall-cell Lung Cancer, Neoadjuvant TherapyArmsAtezolizumab, Carboplatin, Etoposide
3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2021
    Guideline
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Sevoflurane induces CaCytotechnology · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Chi-Fu Jeffrey YangDuke University Medical Center, Durham, NC.
Derek Y ChanDuke University Medical Center, Durham, NC.
Shivani A ShahDuke University Medical Center, Durham, NC.
Babatunde A YerokunDuke University Medical Center, Durham, NC.
Xiaofei F WangDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC.
Thomas A D'AmicoDuke University Medical Center, Durham, NC.
Mark F BerryDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC.
David H HarpoleDuke University Medical Center, Durham, NC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine whether surgery with adjuvant chemotherapy offers a survival advantage over concurrent chemoradiation for patients with cT1-2N0M0 small cell lung cancer (SCLC).

backgroundAlthough surgery with adjuvant chemotherapy is the recommended treatment for patients with cT1-2N0M0 SCLC per international guidelines, there have been no prospective or retrospective studies evaluating the impact of surgery versus optimal medical management for cT1-2N0M0 SCLC.

methodsOutcomes of patients with cT1-2N0M0 SCLC who underwent surgery with adjuvant chemotherapy or concurrent chemoradiation in the National Cancer Data Base (2003-2011) were evaluated using Cox proportional hazards analyses and propensity-score-matched analyses.

resultsDuring the study period, 681 (30%) patients underwent surgery with adjuvant chemotherapy and 1620 (70%) underwent concurrent chemoradiation. After propensity-score matching, all 14 covariates were well balanced between the surgery (n = 501) and concurrent chemoradiation (n = 501) groups. Surgery was associated with a higher overall survival (OS) than concurrent chemoradiation (5-year OS 47.6% vs 29.8%, P < 0.01). To minimize selection bias due to comorbidities, we limited the propensity-matched analysis to 492 patients with no comorbidities; surgery remained associated with a higher OS than concurrent chemoradiation (5-year OS 49.2% vs 32.5%, P < 0.01).

conclusionsIn a national analysis, surgery with adjuvant chemotherapy was used in the minority of patients for early stage SCLC. Surgery with adjuvant chemotherapy for node-negative SCLC was associated with improved long-term survival when compared to concurrent chemoradiation. These results suggest a significant underuse of surgery among patients with early stage SCLC and support an increased role of surgery in multimodality therapy for cT1-2N0M0 SCLC.

Indexed as

ChemoradiotherapyPneumonectomyAgedCombined Modality TherapyFemaleHumansLung NeoplasmsMaleNeoplasm StagingPropensity ScoreSmall Cell Lung CarcinomaSurvival RateTreatment Outcome

Identifiers

PMID28475559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.